Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

Targeted cancer therapies exploit the continued dependence of cancer cells on oncogenic mutations. Such agents can have remarkable activity against some cancers, although antitumor responses are often heterogeneous, and resistance remains a clinical problem. To gain insight into factors that influen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wendel, Hans-Guido, de Stanchina, Elisa, Cepero, Enriqué, Ray, Sagarika, Emig, Michael, Fridman, Jordan S., Veach, Darren R., Bornmann, William G., Clarkson, Bayard, McCombie, W. Richard, Kogan, Scott C., Hochhaus, Andreas, Lowe, Scott W.
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2006
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1455409/
https://ncbi.nlm.nih.gov/pubmed/16651519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0602402103
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars